Clinical trial
Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an…
NCT00238433 · OHSU Knight Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00238433 |
|---|---|
| Title | Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma |
| Official title | A Phase II Study to Evaluate the Safety and Efficacy of IV Busulfan, Melphalan, and Thiotepa (BuMelTT) Followed By Autologous PBSC Infusion for Patients With Hodgkin's Disease and Non-Hodgkin's Lymphoma |
| Lead sponsor | OHSU Knight Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological, Drug, Procedure |
| Interventions | filgrastim, busulfan, melphalan, thiotepa, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation |
| Enrollment | 37 |
| Start date | Mar 1, 2005 |
| Primary completion | Aug 1, 2015 |
| Completion | Dec 1, 2016 |
| First posted | Oct 13, 2005 |
| Last update posted | Sep 27, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: